Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 12/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25004048 | 0.85 | MAP4K1 (0.39) | MAP4K1MAPTAAK1TDO2PIK3CA | |
| SCHEMBL25003435 | 0.84 | MAOA (0.36) | MAP4K1 | |
| SCHEMBL25003720 | 0.84 | MAP4K1 (0.36) | MAP4K1PIK3CA | |
| SCHEMBL25003184 | 0.80 | MAP4K1 (0.36) | MAP4K1MAPTTDO2PIK3CATRPA1 | |
| SCHEMBL25003709 | 0.80 | AAK1 (0.35) | MAP4K1AAK1 | |
| SCHEMBL25003919 | 0.78 | KMT2A (0.34) | MAP4K1AAK1 | |
| SCHEMBL25003412 | 0.77 | ALOX5AP (0.30) | — | |
| SCHEMBL19592858 | 0.70 | PIK3CA (0.42) | MAPTAAK1PIK3CA | |
| SCHEMBL26262829 | 0.69 | MAP4K1 (0.40) | MAP4K1MAPT | |
| SCHEMBL25003722 | 0.68 | MAP4K1 (0.38) | MAP4K1MAPTPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HMBS, AHCY | MAP4K1 4500/4885NR3C1 3196/4885NR3C2 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.